甲氨蝶呤联合阿达木单抗对早期类风湿性关节炎患者血清CD206表达水平的影响

Effect of methotrexate combined with adalimumab on the expression level of serum CD206 in patients with early rheumatoid arthritis

目的 探讨甲氨蝶呤联合阿达木单抗对早期类风湿性关节炎患者血清CD206表达水平的影响。方法 纳入2020年6月至2021年6月收治的90例早期类风湿性关节炎患者为研究对象,采用随机法将其分为单纯组(n=45,甲氨蝶呤)和联合组(n=45,甲氨蝶呤联合阿达木单抗)。比较两组的治疗效果。结果 联合组的治疗总有效率为91.11%,显著高于单纯组的75.56%(P<0.05)。治疗后,联合组的血清CD206、CRP、ESR、RF和Th1细胞水平均低于单纯组,Terg细胞水平高于单纯组(P<0.05)。结论 甲氨蝶呤联合阿达木单抗治疗早期类风湿性关节炎患者效果显著,值得临床应用。

Objective To investigate the effect of methotrexate combined with adalimumab on the expression level of serum CD206 in patients with early rheumatoid arthritis. Methods A total of 90 patients with early rheumatoid arthritis treated from June 2020 to June 2021 were included as the research objects. The patients were divided into simple group(n =45, methotrexate) and combined group(n =45, methotrexate combined with adalimumab) by random method. The therapeutic effects of the two groups were compared. Results The total effective rate of treatment in the combined group was 91.11%, which was significantly higher than 75.56% in the simple group(P <0.05). After treatment, the levels of serum CD206, CRP, ESR, RF and Th1 cells in the combined group were lower than those in the simple group, and the level of Terg cells was higher than that in the simple group(P <0.05). Conclusion Methotrexate combined with adalimumab is effective in the treatment of early rheumatoid arthritis, which is worthy of clinical application.